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Clinical records of 286 consecutive patients reacting positively with objective symptoms to double-blind,
placebo-controlled oral peanut challenges at University Hospital, Nancy, France were examined for indi-
vidual No Observed Adverse Effect Levels (NOAELs) and Lowest Observed Adverse Effect Levels (LOAELs).
After ﬁtting to a log-normal probability distribution model, the ED10 and ED05 were 14.4 and 7.3 mg
(expressed as whole peanut), respectively, with 95% lower conﬁdence intervals of 10.7 and 5.2 mg,
respectively. Compared to results from a previous study where the ED10 was based upon individual pea-
nut thresholds gleaned from 12 publications, a statistically signiﬁcant difference was observed between
the ED50’s, but not the ED10’s of the two probability distribution curves. The Nancy patient group contains
more sensitive subjects than the group from the published literature thus contributing to the observed
differences. Minimum eliciting dose-distributions for patients with histories of more severe reactions
(grade 4 or 5; 40 subjects) did not differ signiﬁcantly from those of patients with histories of less severe
reactions (grades 1–3; 123 subjects). These data and this modeling approach could be used to establish
population thresholds for peanut-allergic consumers and thereby provide a sound basis for allergen con-
trol measures in the food industry.
 2009 Elsevier Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Allergic reactions to peanut are among the most prevalent and
severe of all food allergies (Hourihane et al., 2007; Bock et al.,
2007; Yunginger et al., 1988). The inadvertent ingestion of peanut
by peanut-allergic individuals is the leading cause of fatal food-
allergic reactions (Bock et al., 2007; Yunginger et al., 1988). It has
also been reported that exposure to trace amounts of peanuts
can provoke allergic reactions in some peanut-allergic individuals
(Taylor et al., 2002). Thus, careful and complete avoidance of pea-
nuts has been advised for peanut-allergic individuals (Taylor et al.,
1986). Peanut-allergic consumers face increasingly restricted food
choices in complying with this advice due, in part, to the prolifer-
ation of advisory labels such as ‘may contain peanuts’ (Heﬂe et al.,
2007).
Experience with clinical oral challenge trials indicates that
exposures do exist below which individuals with conﬁrmed peanut
allergy will not experience allergic reactions (Taylor et al., 2002).
An individual’s elicitation threshold lies between the No Observed: +1 402 472 5307.
-NC-ND license. Adverse Effect Level (NOAEL), the highest dose that will not pro-
duce any adverse effect in that person and the Lowest Observed
Adverse Effect Level (LOAEL), the lowest dose that produces an ad-
verse effect (Taylor et al., 2009). The range of LOAEL doses for pea-
nut-allergic individuals in clinical challenge trials spans 4–5 orders
of magnitude – 0.5 mg up to 8000–10,000 mg of whole peanut
(Taylor et al., 2009). The population threshold is deﬁned as the
largest amount of peanut that would not cause an adverse reaction
in any individual within the total population of peanut-allergic
individuals. But, of course, it is impossible to perform challenge
tests on the entire peanut-allergic population, so population
threshold estimates must be obtained from clinical food challenge
trials conducted on deﬁned groups of peanut-allergic individuals.
The accuracy of those population threshold estimates will depend
upon the representativeness of the selected population and the sta-
tistical approach used to model the distribution of the individual
threshold doses from the clinical studies.
The US Food and Drug Administration has indicated that statis-
tically-based risk assessment (including statistical techniques such
as dose-distribution modeling) provides the ideal approach to the
establishment of a population threshold for allergenic foods
including peanut (Threshold Working Group, 2008). Taylor et al.
S.L. Taylor et al. / Food and Chemical Toxicology 48 (2010) 814–819 815(2009) used dose-distribution modeling to estimate the population
threshold from individual threshold information for 185 peanut-
allergic subjects obtained from 12 published clinical studies. From
the NOAELs and LOAELs of these patients, a dose-distribution mod-
el was constructed using interval-censoring survival analysis (Tay-
lor et al., 2009). An ED10 (the dose predicted to provoke a reaction
10% of the peanut-allergic population) of 8.4 mg of whole peanut
was derived based on ﬁtting the data to a log-normal distribution.
In that study, the choice of the probability distribution model had
little effect on the ED10 estimate. While that dataset was the largest
on individual peanut thresholds assembled to date, the sufﬁciency
of these data to establish a population threshold as a basis for risk
management could be questioned. First, these data were obtained
from 12 different published studies using various clinical challenge
protocols. In particular, the use of different challenge doses in the
various protocols created a large number of NOAEL/LOAEL inter-
vals. Furthermore, the LOAEL dose could not be deﬁned in 67/
185 subjects which increases the uncertainty about the ‘‘true” pop-
ulation threshold dose (Taylor et al., 2009). Secondly, patient selec-
tion biases likely existed in these published studies since there was
no evidence to suggest that the peanut-allergic subjects had been
randomly selected. Furthermore, the NOAEL/LOAEL intervals could
only be discerned for a fraction of the total number of peanut-aller-
gic subjects included in these published studies which likely intro-
duces additional bias (Taylor et al., 2009). However, there is
strength in that analysis because the data come from a combina-
tion of 12 studies.
This risk assessment effort (Taylor et al., 2009) demonstrated
that sufﬁcient data exist for peanut to establish an estimate of a
population threshold that could be used for regulatory and food
industry action/management levels. However, because of the uncer-
tainties noted above, a similar analysis based on data obtained from
group(s) of peanut-allergic subjects where a consistent challenge
protocol was used and where the patient population could be ade-
quately characterized and selection biases could be minimized, or
at least better understood would be important in establishing a bet-
ter estimate of the population threshold.We describe the analysis of
a large clinical dataset from University Hospital, Nancy, France
where diagnostic peanut challenges had been conducted on all pro-
spective peanut-allergic patients at that clinic using a consistent
challenge protocol over a period of more than 10 years.2. Patients
Patients (286, 162 males, <1–48 years of age (median 7.0 years))
were selected for diagnostic oral, double-blind, placebo-controlled
peanut challenges (DBPCFC) at University Hospital, Nancy, France
based upon either a history of possible previous allergic reactions
to peanut, including anaphylactic shock, or sensitization to peanuts
detected at an early age but no history of actual allergic reactions
to peanuts as a result of being placed on a systematic avoidance
diet. Apart from being peanut-allergic, they were unselected, con-
secutive patients who attended the clinic as part of the treatment
of their allergy. Consecutive patients include all of the patients that
self-selected to seek medical diagnosis of their peanut allergy at
the Nancy France clinic and were enrolled in a low-dose food chal-
lenge (patients were not randomly selected for challenge).
Although a proportion of patients received more than one peanut
challenge over time, the data used here are from only the initial
diagnostic challenge procedure.3. Methods
DBPCFCs were conducted in a manner consistent with the consensus clinical
protocol for threshold studies (Taylor et al., 2004). Anti-histamine treatment was
stopped 7 days before challenge and inhaled corticosteroids and beta agonists werestopped 24 h before challenge. Patients were not challenged while, or within a week
of suffering respiratory infections or rhinopharyngitis. DBPCFC was conducted on
each subject using various doses of crushed roasted peanut in apple sauce (Moner-
et-Vautrin et al., 1995). An interval of 15 min was used between increasing doses of
peanut. In general, one or two of three series of dosage progressions were used
depending upon the described severity of historical reactions to peanut and the
age of the patient (Table 1). Thus some patients started with Progression 1 while
others started with Progression 2 depending on the physician’s judgment about
their potential reactivity. Occasionally, modiﬁcations of the progression were used
instead. Both subjective and objective symptoms were recorded and generally, chal-
lenges were continued until objective symptoms were encountered or until the
highest dose (7110 mg cumulative dose) had been consumed. Objective symptoms
included any symptom that would have been discernable to clinical observers e.g.
vomiting, urticaria, rash, angioedema, etc. Abdominal pain was considered an
objective reaction only in children who did not experience symptoms in the placebo
arm of the DBPCFC. Additionally, the abdominal pain should have lasted for more
than 30 min or should have been of sufﬁcient intensity to require treatment (gluco-
corticoid and H1 anti-histamine) to be considered an objective endpoint symptom.
Crying; prostration; mood changes (grumbling child); pharyngeal, oral, or laryngeal
pruritis; nausea; or palor were minor criteria that were used to support the abdom-
inal pain symptom. Abdominal pain as the sole symptom was not considered an
objective endpoint symptom in adult subjects. Adult subjects continued with the
challenge until objective symptoms were experienced.
Occasionally, the next higher dose was administered at the physician’s discre-
tion in situations where the initial reaction was very mild and transitory. Individual
NOAELs and LOAELs were recorded for each peanut-allergic patient based upon the
cumulative dose eliciting the initial objective reaction. In the instances where very
mild and transitory reactions were observed and the next higher dose was admin-
istered, the LOAEL was considered the cumulative dose where lasting objective
reactions occurred and the NOAEL was considered the previous cumulative dose.
If no adverse reaction was encountered at the highest dose in Progression 3, then
the patient was not considered as peanut-allergic and was not included in the
dataset.
The records of peanut-allergic patients were also screened for evidence con-
cerning the history of severity of allergic reactions occurring to peanut before
DBPCFC. Patients were identiﬁed as having a previous severe reaction if they gave
a history of a Severity Grade 4 or 5 reaction (objective reactions occurring in three
organ systems, asthma requiring treatment, laryngeal edema, and/or hypotension)
(Astier et al., 2006). Other patients were identiﬁed as having a previous non-severe
reaction if they gave a history of a Severity Grade 1–3 reaction (objective symptoms
occurring in 1–2 organ systems, abdominal pain, rhinoconjunctivitis, urticaria,
eczema, angioedema but not laryngeal edema, and/or asthma not requiring
treatment).
Individual NOAELs and LOAELs for all peanut-allergic patients challenged over a
17-year period from 1991 to 2008 were analyzed by an Interval-Censoring Survival
Analysis (ICSA) approach as previously described (Collett, 1993; Taylor et al., 2009).
Data analyses and modeling were performed in SAS v9.1 (SAS Research Institute)
using the procedure LIFEREG as previously described (Taylor et al., 2009). A log-nor-
mal dose-distribution model was used to estimate the ED10 and the ED05, the doses
predicted to provoke reactions in 10% and 5%, respectively, of the peanut-allergic
population.
4. Results
4.1. Dose-distributions
Individual NOAELs and LOAELs based on objective symptoms
for whole peanut were obtained for 286 patients over the 17-year
time period. The ED10 and ED05 were 14.4 and 7.3 mg (expressed as
whole peanut), respectively, with 95% lower conﬁdence intervals
of 10.7 and 5.2 mg, respectively (Table 2). Fig. 1 shows that differ-
ences were observed between the slope of the curve of the log-nor-
mal distribution model for this dataset and the distribution
modeled separately from the evaluation of the individual thresh-
olds of peanut-allergic subjects gleaned from the published clinical
literature (Taylor et al., 2009). This difference is also reﬂected in
the ED50 values (the dose predicted to provoke reactions in 50%
of the peanut-allergic population) which were 1036 mg of whole
peanut for publications dataset and 157 mg of whole peanut for
the Nancy patient dataset. Since the 185 peanut-allergic subjects
included in the original analysis of the individual thresholds of
peanut-allergic subjects from the published literature included
21 subjects reported by the clinical group in Nancy, France (Taylor
et al., 2009), those data points were removed before the dose-dis-
tribution modeling shown in Fig. 1 – an analysis of the remaining
Table 1
DBPCFC dose progression series.
Progression 1 Progression 2 Progression 3
Dose Cumulative dose Dose Cumulative dose Dose Cumulative dose
0.1 0.1 5.0 5.0 10.0 10.0
0.3 0.4 10.0 15.0 100.0 110.0
1.0 1.4 50.0 65.0 500.0 610.0
3.0 4.4 150.0 215.0 1500.0 2110.0
10.0 14.4 285.0 500.0 5000.0 7110.0
30.0 44.4 465.0 965.0
All values reported in milligram whole peanut.
Table 2
ED10 and ED05 doses for whole peanut as assessed by the log-normal probability
distribution models.
Source Total no. of peanut-allergic
individuals
ED10 95% CI ED05 95%
CI
Nancy data 286 14.4 10.7,
19.6
7.3 5.2,
10.4
Published
papersa
164 14.1 6.6,
29.9
4.2 1.7,
10.1
Combined 450 12.3 9.0,
16.8
5.2 3.6,
7.4
All values reported in mg of whole peanut.
a Nine published studies yielded NOAELs and LOAELs for 164 peanut-allergic
individuals. Twenty-one individuals from three papers (A, B, and D; see Taylor et al.,
2009) were excluded from analysis to avoid potential duplication of individuals as
these studies included individuals from the Nancy clinic.
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bined dataset of 450 peanut-allergic subjects are presented in Ta-
ble 2. The removal of the 21 Nancy patients from the original
dataset caused the ED10 to increase from 8.4 to 14.1 mg because
many of these subjects were among the most sensitive in that
dataset. Four of these 21 subjects were left-censored individuals
that reacted upon ingestion of the ﬁrst dose (5 mg of whole pea-
nut) in the challenge. The left-censored subjects have a profound
effect in lowering the overall population threshold and, by taking
these individuals out of the publications dataset, the overall ED10
estimate increased. This clearly shows the importance of designing
low-dose challenge studies so that all individuals are interval-cen-
sored (have established NOAEL and LOAEL values). The ED10 andFig. 1. Log-normal probability distribution models of individual peanut thresholds (expre
compiled from diagnostic challenge trials in Nancy, France.ED05 from this Nancy dataset are slightly higher than the estimates
obtained from the evaluation of individual thresholds gleaned from
the published literature (Table 2). From the combined dataset of
450 peanut-allergic subjects, the ED10 and ED05 were 12.3 and
5.2 mg (expressed as whole peanut), respectively, with 95% lower
conﬁdence intervals for the ED10 and ED05 of 9.0 and 3.6 mg,
respectively (Table 2). The slight decrease in the ED10 and ED05 val-
ues in the combined dataset compared to the Nancy dataset can be
attributed to the inclusion of three very sensitive interval-censored
subjects (LOAEL values ranging from 0.5 to 1.6 mg) and ﬁve left-
censored individuals from the publications dataset (164 total sub-
jects) that, when analyzed with the more sensitive subjects in the
Nancy dataset, further decreases the ED10 and ED05 values for the
combined dataset. The estimates from the combined dataset and
the Nancy dataset, however, are not signiﬁcantly different.4.2. Responses to challenge
Many of the subjects experiencedmultiple symptoms during the
oral challenge. All of these symptoms are summarized in Table 3,
both overall and according to dose progression, to which they had
been allocated according to the physician’s initial view of likely
reactivity. Thus individuals whowere thought likely to react at very
low doseswere started at 0.1 mg and challenged up to 44.4 mg. This
ensured that an individual NOAEL was obtained for all but eight
subjects. Almost all symptoms observed during challenges in all
groups were mild. Adult subjects who experienced abdominal pain
as their only initial symptom were continued in the oral challenge
until objective symptoms were observed. In all cases, more severessed as whole peanut) for peanut-allergic individuals gleaned from publications and
Table 3
Summary of symptoms* reported on challenge for 286 peanut-allergic individuals.
Symptoms Progression 1 Progression 2 Progression 3 Total
Number of
reactions
% Number of
reactions
% Number of
reactions
% Number of
reactions
%
Conjunctivitis 3 5 27 14 5 14 35 12
Rhinitis 2 3 29 15 5 14 36 13
Hives 5 9 34 18 18 50 57 20
Angioedema 3 5 13 7 5 14 21 7
Rash or eczema 2 3 14 7 7 19 23 8
Sibilant rales (wheeze)a 2 3 24 13 6 17 32 11
Decrease PEF (20%) 0 0 22 11 4 11 26 9
Asthma 2 3 27 14 4 11 33 12
Tachycardia 0 0 11 6 5 14 16 6
Fall of BP 0 0 4 2 1 3 5 2
Vomiting 6 10 57 30 4 11 67 23
Abdominal pain (+ other symptoms) 30 52 117 61 17 47 164 57
Abdominal pain only 17 29 32 17 4 11 53 19
Diarrhea 4 7 12 6 2 6 18 6
Other objective symptoms 3 5 34 18 7 19 44 15
Subjective symptoms 15 26 66 34 10 28 91 32
Total number of peanut-allergic
individuals
58 192 36 286
Males 37 106 19 162
Females 21 86 17 124
Age (years) (median; range) 7.5 2.9–25 7.0 <1–48 5.5 1.4–22 7.0 <1–48
*Many subjects experienced multiple symptoms during the double-blind, placebo-controlled food challenge (DBPCFC). All symptoms were recorded according to the dose
progression where the reactions occurred and total number of reactions for each symptom is provided.
a Sibilant rales (wheeze) are heard by auscultation and are the ﬁrst sign of asthma crisis. Asthma was used only to describe when a subject was dyspnoeic.
Table 4
ED10 doses* for whole peanut as assessed by the log-normal probability distribution
model for Severity Grade.
Severity grade Total no. of peanut-allergic individuals ED10 95% CI
Severea 40 10.4 4.8, 22.6
Non-severeb 123 10.2 6.4, 16.1
No prior historyc 123 27.0 17.4, 42.0
All values reported in mg whole peanut.
*Statistically valid ED05 estimates could not be provided due to the limited number
of subjects in all of the severity grade classes.
a Severe reactions include three organ systems, asthma requiring treatment,
laryngeal edema, and/or hypotension.
b Non-severe reactions include one or two organ systems, abdominal pain, rhi-
noconjunctivitis, urticaria, eczema, non-laryngeal angioedema, and/or mild asthma
(peak ﬂow rate <80%).
c History of prior allergic reactions and severity of reactions were not available.
These individuals were identiﬁed as being sensitized to peanut by means of diag-
nostic tests.
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ingestion of increasing doses. A similar observation was also made
by Ballmer-Weber et al. (2007) where 5 soy-allergic subjects with
initial abdominal pain reacted with objective symptoms upon
increasing the dose. More severe symptoms, such as a fall in blood
pressure, were only observed occasionally, while they were never
observed during Progression 1 (low dose). Interestingly, the symp-
toms experienced by those who reacted to the ﬁrst (low dose) pro-
gression showed, if anything, somewhat milder symptoms than the
other two groups. The most common symptoms were linked to the
gastrointestinal tract, namely abdominal pain (includes those expe-
riencing abdominal pain only and abdominal pain plus other symp-
toms) and vomiting, which were experienced by approximately
76% and 23% of patients, respectively.
4.3. Severity by history vs. reactive dose
Among the 286 peanut-allergic patients from Nancy, 163 sub-
jects had experienced a reaction prior to challenge and information
was available on the severity of those reactions. A total of 40 sub-
jects were identiﬁed who had previously experienced severe reac-
tions (Severity Grade 4 or 5) before the DBPCFC compared to 123
subjects who had experienced less severe reactions (Severity Grade
1–3). The threshold distribution of patients with histories of more
severe reactions did not differ signiﬁcantly from the threshold dis-
tributions from patients with histories of less severe reactions
(data not shown). The ED10’s for the two groups were quite similar
(Table 4). In contrast, the ED10 for the remaining 123 patients, most
of who did not present initially with a history of an allergic reac-
tion to peanut was somewhat higher, although this difference
was not statistically signiﬁcant (Table 4). Previous oral exposure
to peanut is uncertain in this group.
5. Discussion
Thresholds are needed to assess the risk posed by residues of
allergenic foods particularly at the population level and to deter-
mine appropriate risk management strategies. Population thresh-olds are critical to the assessment of public health risk, the
development of appropriate risk management approaches, and
the establishment of regulatory safeguards for allergic consumers.
Dose-distribution probability modeling has been identiﬁed as a
promising approach to estimate population thresholds (Bindslev-
Jensen et al., 2002; Crevel et al., 2007). While the US Food and Drug
Administration indicated that such modeling would provide the
ideal approach to the establishment of population thresholds for
allergenic foods including peanut (Threshold Working Group,
2008), they have questioned whether enough data exist for such
modeling. Recently, we demonstrated that sufﬁcient data could
be gleaned from the published literature for peanut to estimate
doses predicted to elicit (mild) reactions (Perry et al., 2004) in
10% of the at-risk population with reasonable precision (Taylor
et al., 2009).
We have now conﬁrmed and strengthened our initial esti-
mate of the population threshold for peanut. Individual NOAELs
and LOAELs were found, respectively, for 278 and 286 peanut-
allergic subjects by screening the records of University Hospital,
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from this dataset is in reasonable agreement with the earlier
estimate (8.4 mg) by the log-normal distribution model. When
the 21 subjects from the Nancy clinic were removed from the
earlier dataset to avoid possible duplications, the ED10 increased
to 14.1 mg. These 21 subjects were among the most sensitive
and included four left-censored subjects in the earlier dataset
accounting for the difference. Some patient selection bias is
obvious because the NOAELs and LOAELs of only the 10 most
sensitive of 103 peanut-allergic patients could be discerned from
one of those earlier Nancy publications (Morisset et al., 2003;
Taylor et al., 2009). Furthermore, combining the two datasets al-
lowed the estimation of the ED10 and the ED05 based on the
NOAELs and LOAELs of 450 peanut-allergic subjects with a high-
er level of conﬁdence. While the ED10’s for the two datasets are
quite similar, the dose-distribution curves are strikingly different
as reﬂected in Fig. 1 and by the ED50’s. The difference indicates
that the Nancy dataset is weighted toward more sensitive pea-
nut-allergic subjects.
The data on NOAELs and LOAELs from the Nancy patients offer
some distinct advantages in comparison to the use of the informa-
tion from the published literature. Population thresholds should
ideally be based upon clinical data obtained from a representative
sample of the entire peanut-allergic population. The published
studies examined for our earlier population threshold estimate
(Taylor et al., 2009) involved selected patients and were highly het-
erogeneous. NOAELs and LOAELs could only be identiﬁed or dis-
cerned for a proportion of the total number of subjects from
some publications considered in the earlier study (Taylor et al.,
2009). In contrast, the Nancy subjects were 286 consecutive pa-
tients with positive peanut challenges. The patient selection bias
is thus reduced although the subjects do self-select to seek the
medical diagnosis of their peanut allergy. Furthermore, the Nancy
challenge protocol with three dosing progressions enhances the
likelihood that the dosage range will encompass both the NOAEL
and LOAEL. In fact, no right-censored subjects (LOAEL > highest
challenge dose) were encountered in the Nancy group (such sub-
jects would have been considered not to be peanut-allergic), while
67 such individuals were included among the 185 subjects in the
earlier analysis (Taylor et al., 2009). The number of left-censored
subjects (LOAEL = lowest challenge dose) was similar in the Nancy
group (eight left-censored subjects) and the published studies
group (nine left-censored individuals) (Taylor et al., 2009). Subse-
quently, we have re-analyzed the dose-distributions from the pub-
lications dataset with and without inclusion of the right-censored
subjects (Table 5). The ED10 is slightly lower for the distribution
without any right-censored subjects (6.1 mg of whole peanut) by
comparison to the group that contains the 67 right-censored sub-
jects (14.1 mg of whole peanut). Typically, clinical challenge trialsTable 5
ED10 and ED05 doses for whole peanut as assessed by the log-normal probability
distribution model for inclusion of the right-censored subjects in the publications
dataset.
Group Total no. of peanut-allergic
individuals
ED10 95%
CI
ED05 95%
CI
Right-
censoreda
164 14.1 6.6,
29.9
4.2 1.7,
10.1
Non-right-
censoredb
97 6.1 2.8,
13.2
2.2 0.9,
5.4
All values reported in mg of whole peanut.
a Nine published studies yielded NOAELs and LOAELs for 164 peanut-allergic
individuals, 67 of which were right-censored (see Taylor et al., 2009).
b Non-right-censored dataset contains NOAELs and LOAELs for 97 peanut-allergic
individuals from the published studies that are either left-censored or interval-
censored.are limited to several hours, leading to practical limitations in
designing experiments that would ensure the identiﬁcation of both
NOAELs and LOAELs for all subjects. Thus, the use of the three dos-
age progressions in the Nancy clinic allowed determination of the
individual NOAELs and LOAELs for all peanut-allergic subjects.
Another uncertainty regarding the development of population
thresholds for peanut is the possible exclusion of patients with his-
tories of severe reactions from clinical challenge trials (Taylor et al.,
2002). Without studies on patients with histories of severe reac-
tions, the possibility exists of a more sensitive sub-population,
which might remain unprotected if risk management was based
on the response of the less sensitive majority. In the previous esti-
mate of the population threshold for peanut (Taylor et al., 2009),
the selection of patients and the severity of the symptoms involved
in their previous reactions was impossible to determine. However,
in the Nancy group, patients with previous histories of severe reac-
tions, including anaphylactic shock, were not excluded from the
diagnostic challenges. Of 163 challenged patients with known pre-
vious histories of allergic reactions to peanut, 40 subjects had his-
tories of severe reactions. But, as shown in Table 4, the ED10 for the
severe reactors was essentially the same as that of the non-severe
reactors. Thus, subjects with histories of severe allergic reactions to
peanuts do not appear to represent a distinct sub-population with
greater sensitivity. Interestingly, the ED10 for the remaining 123
subjects, most of whom had no history of previous reactions to
peanuts, was higher. However, the eliciting doses for this group
were still sufﬁciently low to indicate that they would be at risk
from the ingestion of peanut. When setting action levels for regu-
latory purposes, the key criterion is safety. While it is impossible to
be sure of protecting every single allergic individual against a reac-
tion, it is important to demonstrate that, in the event of inadver-
tent exposure, any reaction will be mild. The data on the most
sensitive individuals, namely those who reacted to the lowest
amounts of peanut offer considerable reassurance in this respect,
since all of them showed mild symptoms at the doses which elic-
ited reactions (Table 3).
Using the combined dataset of 450 peanut-allergic individuals
allows prediction of the ED10 and ED05 with a high level of conﬁ-
dence. In our opinion, these data should be considered for use by
regulatory and public health authorities in the establishment of
population thresholds for peanut. Data should also be gathered
on individual NOAELs and LOAELs for other commonly allergenic
foods to determine if their threshold levels are similar to peanut.
However, lesser amounts of data are likely available than for
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